Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical (NYSE:TAK) has filed its annual Form 20-F report for foreign issuers. The filing appears to be a standard annual report containing detailed financial information, segment performance data, and regulatory disclosures across their pharmaceutical product portfolio including key drugs like Entyvio, Takhzyro, and Vyvanse. The report includes comprehensive breakdowns of revenue by therapeutic areas including Gastroenterology, Rare Diseases, PDT (Plasma-Derived Therapies), Oncology, Vaccines, and Neuroscience segments.
Takeda Pharmaceutical Company Limited (NYSE:TAK) filed a Form 6-K reporting the outcome of its 149th Annual Meeting of Shareholders and subsequent Board of Directors meeting held on 25 June 2025. The filing focuses exclusively on corporate governance matters and contains no financial performance data.
Board composition: The Board remains at 14 members, of which 11 (≈79%) are external directors. An external director, Masami Iijima, continues to chair the Board, underscoring Takeda’s commitment to independent oversight.
Key assignments (effective 25 June 2025):
- Christophe Weber retains dual roles as Representative Director and President & CEO.
- Milano Furuta remains Director & CFO; Andrew Plump continues as Director, President, R&D.
- Audit & Supervisory Committee: Headed by Koji Hatsukawa with three additional external members; all are within their two-year tenure and were not up for re-election.
- Nomination Committee: Six external directors; chaired by Masami Iijima. CEO Christophe Weber attends as observer only.
- Compensation Committee: Five external directors; chaired by Emiko Higashi.
Governance implications: Committees composed solely of independent directors, coupled with an external board chair, align with best-practice governance standards designed to enhance transparency, mitigate conflicts of interest, and safeguard minority shareholder rights. No changes were announced to strategic direction, capital allocation, or executive compensation structures beyond committee assignments.
Takeda Pharmaceutical held its 149th Annual General Meeting of Shareholders on June 25, 2025, where several key resolutions were passed. The meeting addressed the company's performance for FY2024 (April 1, 2024 to March 31, 2025).
Key resolutions approved include:
- Approval of a year-end dividend of 98 JPY per share
- Re-election of ten Directors not serving on the Audit and Supervisory Committee, including CEO Christophe Weber and seven External Directors
- Approval of executive bonuses totaling up to 460 million JPY for two eligible Directors (excluding overseas Directors and External Directors)
The meeting also reviewed the Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements, along with audit results from the Accounting Auditor and Audit and Supervisory Committee. This filing demonstrates Takeda's commitment to corporate governance and shareholder transparency.